ArticleJACC. Advances2025
Efficacy of Coronary Sinus Aspiration in Reducing Contrast-Induced Nephropathy in High-Risk Patients.
Article in JACC. Advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContrast-induced nephropathy (CIN) is a complication of angiographic procedures. Coronary sinus aspiration (CSA) is a novel technique aimed at reducing renal exposure to contrast and mitigating the risk of CIN.
objectivesThe aim of the study was to evaluate the rates of CIN in high-risk patients with and without CSA at the time of coronary angioplasty.
methodsIn this single-center, prospective, single-blind randomized controlled trial, 70 high-risk patients undergoing coronary angioplasty were randomized into 2 groups: the intervention group (coronary angioplasty with CSA) and the control group (coronary angioplasty). The primary outcome was the proportion of patients developing CIN (defined as an increase in serum creatinine of at least 25% or 0.5 mg/dL within 3 days following the procedure).
resultsIn total, 70 patients with diabetes and chronic kidney disease 3 (mean age 60.6 ± 8.7 years) were included. Of the 37 participants initially allocated to CSA, 4 were excluded (3 due to difficulties in coronary sinus cannulation and 1 due to a procedural complication). The mean volume of injected contrast was 65.2 ± 23 mL and the estimated volume of aspirated contrast was 18.7 ± 7.1 mL. Among the 66 remaining patients, the rate of CIN was lower in the intervention group (5/33, 15.2%) compared to the control group (13/33, 39.4%) (P = 0.027). There were no differences in postprocedural serum creatinine and estimated glomerular filtration rate.
conclusionsWhile CSA was associated with lower rates of CIN in high-risk patients undergoing coronary angioplasty, procedural complications can occur. Larger studies are needed to understand the role of CSA for high-risk patients undergoing coronary angioplasty.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.